0.00
price down icon100.00%   -54.65
after-market Handel nachbörslich: 54.70 54.70 +
loading
Schlusskurs vom Vortag:
$54.65
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$4.50B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
0.00
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$57.35

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name
Firmenname
Akero Therapeutics Inc
Name
Telefon
650-487-6488
Name
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
67
Name
Twitter
@akerotx
Name
Nächster Verdiensttermin
2025-08-08
Name
Neueste SEC-Einreichungen
Name
AKRO's Discussions on Twitter

Compare AKRO vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AKRO
Akero Therapeutics Inc
0.00 4.50B 0 -269.44M -262.63M -3.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
451.59 118.41B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
744.12 80.02B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
684.77 43.52B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
314.80 42.29B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
282.29 32.13B 5.36B 287.73M 924.18M 2.5229

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-04 Fortgesetzt H.C. Wainwright Buy
2025-08-04 Eingeleitet TD Cowen Buy
2025-01-30 Hochstufung BofA Securities Neutral → Buy
2025-01-27 Bestätigt H.C. Wainwright Buy
2024-11-18 Eingeleitet Citigroup Buy
2024-04-22 Fortgesetzt BofA Securities Neutral
2023-09-19 Eingeleitet Cantor Fitzgerald Overweight
2023-08-28 Eingeleitet UBS Buy
2023-01-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-09-14 Hochstufung Evercore ISI In-line → Outperform
2021-10-19 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-10 Eingeleitet BofA Securities Buy
2021-02-26 Eingeleitet Guggenheim Buy
2020-09-10 Eingeleitet Morgan Stanley Overweight
2020-07-20 Bestätigt H.C. Wainwright Buy
2020-07-07 Eingeleitet Chardan Capital Markets Buy
2020-07-01 Bestätigt H.C. Wainwright Buy
2020-03-02 Eingeleitet H.C. Wainwright Buy
2020-02-10 Eingeleitet Canaccord Genuity Buy
2019-07-15 Eingeleitet Evercore ISI Outperform
2019-07-15 Eingeleitet JP Morgan Overweight
2019-07-15 Eingeleitet Jefferies Buy
2019-07-15 Eingeleitet ROTH Capital Buy
Alle ansehen

Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten

pulisher
Mar 17, 2026

Signal Recap: How does Akero Therapeutics Inc score in quality rankings2026 Biggest Moves & Long-Term Safe Investment Ideas - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 11, 2026

Published on: 2026-03-11 23:57:58 - baoquankhu1.vn

Mar 11, 2026
pulisher
Mar 06, 2026

Panic Selling: What is Akero Therapeutics Incs revenue forecastWeekly Market Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

Treasury Yields: Is Akero Therapeutics Inc stock good for income investorsEarnings Recap Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 05, 2026

Understanding Momentum Shifts in (AKRO) - Stock Traders Daily

Mar 05, 2026
pulisher
Mar 05, 2026

What’s Driving The Super Rally In Akero Shares On Thursday Morning? - Stocktwits

Mar 05, 2026
pulisher
Feb 28, 2026

Published on: 2026-03-01 05:11:32 - baoquankhu1.vn

Feb 28, 2026
pulisher
Feb 24, 2026

Aug Chart Watch: Can Akero Therapeutics Inc maintain sales growthDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 24, 2026

Short Covering: Does Akero Therapeutics Inc meet Warren Buffetts criteriaPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 24, 2026

Macro Review: Is Akero Therapeutics Inc stock influenced by commodity pricesGap Down & AI Forecasted Entry/Exit Points - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 23, 2026

AKRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 23, 2026
pulisher
Feb 22, 2026

Is Akero Therapeutics Inc. stock a falling knife or bargain buyRecession Risk & AI Powered Market Trend Analysis - mfd.ru

Feb 22, 2026
pulisher
Feb 20, 2026

Resistance Check: Can Akero Therapeutics Inc stock outperform in a bear marketJuly 2025 Selloffs & Precise Buy Zone Identification - baoquankhu1.vn

Feb 20, 2026
pulisher
Feb 18, 2026

Merger Talk: Is Akero Therapeutics Inc backed by strong institutional buying2025 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn

Feb 18, 2026
pulisher
Feb 17, 2026

Is Akero Therapeutics Inc. backed by strong institutional buyingJuly 2025 Fed Impact & Stock Market Timing Techniques - mfd.ru

Feb 17, 2026
pulisher
Feb 17, 2026

Akero Therapeutics (NASDAQ: AKRO) holder Janus Henderson now at 4.1% - Stock Titan

Feb 17, 2026
pulisher
Feb 17, 2026

Weekly Earnings: Does Akero Therapeutics Inc have consistent dividend growthMarket Risk Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn

Feb 17, 2026
pulisher
Feb 17, 2026

Growth Value: Can Solid Biosciences Inc withstand a market correctionMarket Sentiment Review & Smart Allocation Stock Reports - baoquankhu1.vn

Feb 17, 2026
pulisher
Feb 17, 2026

RTW Investments exits Akero Therapeutics (AKRO), reporting 0.0% ownership - Stock Titan

Feb 17, 2026
pulisher
Feb 15, 2026

Can Akero Therapeutics Inc. maintain its current growth rateJuly 2025 PreEarnings & High Yield Equity Trading Tips - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

Pullback Watch: Should you avoid Akero Therapeutics Inc stock right now2025 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn

Feb 14, 2026
pulisher
Feb 14, 2026

What’s Akero Therapeutics Inc.’s historical returnPortfolio Performance Report & Daily Risk Controlled Trade Plans - mfd.ru

Feb 14, 2026
pulisher
Feb 13, 2026

Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN

Feb 13, 2026
pulisher
Feb 13, 2026

Aug Wrap: Is Akero Therapeutics Inc. stock showing strong momentumPrice Action & Safe Entry Point Alerts - mfd.ru

Feb 13, 2026
pulisher
Feb 13, 2026

Can Akero Therapeutics Inc. maintain sales growthCPI Data & Daily Entry Point Trade Alerts - mfd.ru

Feb 13, 2026
pulisher
Feb 12, 2026

Analyst Downgrade: Is Akero Therapeutics Inc stock good for income investors2025 Investor Takeaways & High Yield Stock Recommendations - baoquankhu1.vn

Feb 12, 2026
pulisher
Feb 11, 2026

TD Cowen Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN

Feb 11, 2026
pulisher
Feb 10, 2026

Is Akero Therapeutics Inc. stock affected by interest rate hikesJuly 2025 WrapUp & AI Powered Market Entry Strategies - mfd.ru

Feb 10, 2026
pulisher
Feb 02, 2026

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating Growth in Biotechnology with a 3.39% Potential Upside - DirectorsTalk Interviews

Feb 02, 2026
pulisher
Jan 31, 2026

Behavioral Patterns of AKRO and Institutional Flows - Stock Traders Daily

Jan 31, 2026
pulisher
Jan 27, 2026

Analyst Calls: Is Akero Therapeutics Inc stock showing strong momentumPortfolio Growth Summary & AI Powered Market Trend Analysis - baoquankhu1.vn

Jan 27, 2026
pulisher
Jan 27, 2026

Aug Movers: Is Akero Therapeutics Inc. stock influenced by commodity prices2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru

Jan 27, 2026
pulisher
Jan 26, 2026

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring the 3.39% Potential Upside in Biotech Innovation - DirectorsTalk Interviews

Jan 26, 2026
pulisher
Jan 22, 2026

Does Akero Therapeutics Inc. have consistent dividend growth2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru

Jan 22, 2026
pulisher
Jan 22, 2026

Investment Report: Will Akero Therapeutics Inc outperform the market in YEARJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Jan 22, 2026
pulisher
Jan 22, 2026

Income Plays: Is INTU a stock for growth or value investorsJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn

Jan 22, 2026
pulisher
Jan 21, 2026

Guidance Update: What is the earnings history of Akero Therapeutics Inc2025 Volume Leaders & Safe Capital Growth Tips - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 20, 2026

(AKRO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Jan 20, 2026
pulisher
Jan 20, 2026

Quarterly Trades: How does ProShares Trust ProShares UltraPro Short QQQ perform in inflationary periodsJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn

Jan 20, 2026
pulisher
Jan 19, 2026

In Vivo’s Deals Of The Year: Cast Your Vote! - Citeline News & Insights

Jan 19, 2026
pulisher
Jan 19, 2026

RSI Check: Does Akero Therapeutics Inc meet Warren Buffetts criteriaJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 19, 2026

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring Growth Potential Amid a 3.39% Upside - DirectorsTalk Interviews

Jan 19, 2026
pulisher
Jan 18, 2026

Sentiment Recap: Does Akero Therapeutics Inc meet Warren Buffetts criteriaWeekly Risk Report & Smart Swing Trading Alerts - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 17, 2026

Akero Therapeutics shareholders approve Novo Nordisk merger - MSN

Jan 17, 2026
pulisher
Jan 16, 2026

December blockbusters push biopharma deal value to record high - BioWorld MedTech

Jan 16, 2026
pulisher
Jan 15, 2026

Q4 Activity Finishes Off Stronger Biopharma M&A Year In 2025 - Citeline News & Insights

Jan 15, 2026
pulisher
Jan 14, 2026

Aug Technicals: Is CKX Lands Inc a potential multi baggerMarket Activity Recap & Daily Profit Focused Stock Screening - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 13, 2026

Inflation Data: Is ISPC still a buy after recent gainsJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 13, 2026

Published on: 2026-01-14 06:28:29 - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 13, 2026

Insider Buy: What is Akero Therapeutics Incs revenue forecastJuly 2025 Earnings & Safe Capital Investment Plans - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 12, 2026

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating the Biotech’s 3.39% Potential Upside - DirectorsTalk Interviews

Jan 12, 2026

Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$45.79
price down icon 0.69%
$27.80
price down icon 1.77%
$52.40
price down icon 2.84%
$90.00
price down icon 5.12%
$142.70
price down icon 0.85%
biotechnology ONC
$282.29
price down icon 1.75%
Kapitalisierung:     |  Volumen (24h):